Your Health, We Care
Release date: 2024-08-09 15:48:28 Recommended: 122
Capmatinib is a lung cancer drug that targets specific genetic mutations, especially for patients with non-small cell lung cancer with METex14 skipping mutations. The drug helps to stop the proliferation of pathological cells by inhibiting the MET signaling pathway.
It is also important to understand the precautions for the use of ticamatinib during treatment. Here are the details:
Patients should be closely monitored for new or worsening pulmonary symptoms while receiving capmatinib. After the diagnosis of ILD or pneumonia, capmatinib should be discontinued immediately and permanently.
Regular liver function tests are necessary to detect and assess the severity of adverse effects in a timely manner. Depending on the test results, your doctor may recommend stopping the drug, reducing the dose, or permanently stopping capmatinib.
There are also some important drug interactions that patients need to be aware of when using this drug. According to the drug leaflet, here are a few interactions regarding the use of capmatinib:
Interaction of strong inhibitors of CYP3A
CYP3A is an important drug-metabolizing enzyme in the human body and is involved in the metabolic process of a variety of drugs. When CYP3A is subjected to strong inhibitors, the metabolic activity is significantly inhibited, resulting in the accumulation of drugs metabolized by CYP3A in the body, which may cause serious adverse reactions.
Capmatinib should be avoided concomitantly with strong CYP3A inhibitors, including but not limited to antifungal drugs such as itraconazole, ketoconazole, voriconazole, and antiviral drugs such as atazanavir and ritonavir, as well as antibiotics such as clarithromycin and certain foods such as grapefruit. These substances can significantly inhibit the activity of CYP3A, increasing the risk of drug toxicity.
Before purchasing and using drugs, it is also important to understand the information about the use of drugs for special populations, which is organized according to the drug instructions as follows:
Capmatinib can cause harm to the fetus, and animal studies have shown that giving it during pregnancy can cause malformations. There is a lack of data on human pregnant women, and pregnant women are advised to avoid this drug and understand the potential risks in advance.
There is currently no data on whether capmatinib or metabolites enter breast milk and its effects on nursing infants. Serious adverse effects of the drug may occur in infants, and it is recommended to avoid breastfeeding during treatment and for 1 week after the last dose.
[Warm tips] During the medication, patients should be regularly assessed and monitored by a doctor to keep a close eye on their physical condition.
